Treatment for Crohn’s disease is set to change in the future after NICE published draft recommendations.
The body has issued guidance on new and established treatments for the disease in patients of all ages. For example, nurses and other healthcare professionals can use glucocorticosteroids to induce remission, while azathioprine or mercaptopurine can be used as maintenance treatments.
Other draft recommendations made by NICE include discussing the nature of the disease with the patient or the carer to inform them of their options for managing the disease.
The pros and cons of choosing to have or not to have treatment should be covered in these consultancy sessions and the patient’s views should be noted.
NICE’s director of the centre for clinical practice Mark Baker said: “Crohn’s disease is a serious, life-long condition that can significantly affect a person’s quality of life. We are now seeing increasing numbers of people being diagnosed with the disease, and it is particularly common in younger people.
“In the last ten years, there have been a number of new drugs licensed for the condition, so we are sure this new guideline will be a useful aid to all those involved in its treatment.
“We would urge all those registered as stakeholders in the development of this guideline to have their say on our draft recommendations, and submit their comments via the NICE website.”